Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Paran, Yael; Saiag, Esther; Spitzer, Avishay; Angel, Yoel; Yakubovsky, Michal; Padova, Hagit; Ben‐Ami, Ronen; Goldinger, Ilana; Gamzu, Ronni; Sprecher, Eli; Zeltser, David; Henig, Oryan

doi:10.1093/ofid/ofab656

Cited by 12 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with data on the general population [ 32 ], the drop in antibody titers observed around the 6th month, following the second vaccine dose administration, raises some concerns on the potential waning of immunity. This aspect is particularly true in immunodepressed patients and supports the necessity of a third and even a fourth booster dose to ameliorate their safety profile [ 33 ].…”

Section: Resultsmentioning

confidence: 64%

Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Hemodialysis patients (HD) and kidney transplant recipients (KTRs) have been heavily impacted by COVID-19, showing increased risk of infection, worse clinical outcomes, and higher mortality rates than the general population. Although mass vaccination remains the most successful measure in counteracting the pandemic, less evidence is available on vaccine effectiveness in immunodepressed subjects previously infected and recovered from COVID-19. Materials and Methods: This study aimed at investigating the ability to develop an adequate antibody response after vaccination in a 2-dose series against SARS-CoV-2 in HD patients and KTR that was administered after laboratory and clinical recovery from COVID-19. Results: Comparing SARS-CoV-2 S1/S2 IgG levels measured before and after 2 doses of mRNA vaccine (BNT162b2 vaccine, Comirnaty, Pfizer–BioNTech or mRNA-1273 vaccine, Spikevax, Moderna), highly significant increases of antibody titers were observed. The antibody peak level was reached at 3 months following second dose administration, regardless of the underlying cause of immune depression and the time of pre-vaccine serology assessment after negativization. Conclusions: Our data indicate that HD patients and KTR exhibit a satisfying antibody response to a 2-dose series of mRNA vaccine, even in cases when infection-induced humoral immunity was poor or rapidly fading. Further studies are needed to evaluate the role of booster doses in conferring effective and durable protection in weak patient categories.

show abstract

Section: Resultsmentioning

confidence: 64%

Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The more information that can be realized, the better it is for people to select the appropriate brand of vaccine [ 2 , 14 ]. According to an Israeli study, the third dose of BNT162b2 was linked to modest short-term local and systemic responses, which were more common in younger vaccinees [ 7 ]. Another study on primary series found that post-vaccination adverse outcomes in BNT162b2 and ChAdOx1 differed by gender [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…The lack of post-vaccination surveillance and real-world data support made it difficult to select the most appropriate vaccine [ 3 ]. Although many countries had national or hospital-based self-reporting surveillance systems in place, such as the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VAS) in the United States and the Yellow Card Scheme in the United Kingdom [ 4 , 5 ], only a few studies examined the AE of the mix-and-match booster method [ 6 , 7 ]. As more and more brands of the COVID-19 vaccine were introduced into clinical use, multiple combinations of primary boosters were presented.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose

Chen

et al. 2022

Vaccines

View full text Add to dashboard Cite

With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce. The aim of our study was to analyze the reported incidence rate (IR), and factors associated with AE, including short-term serious adverse events (SAE) and short-term non-serious adverse events (NSAE), among different vaccine products through the hospital-based Vaccine Adverse Event Reporting System (VAERS). A total of 7432 records were collected during the three-month study period. While more than half of the responses (52.2%) reported the presence of AE after receiving a booster dose, only a few AE were considered SAE (2.4%). AE were significantly higher among women and people of younger age, and the brand of vaccines is the strongest factor associated with post-booster dose AE. The incidence of AE in mRNA1273 is higher than in BNT162b2 and MVC-COV1901 (IRR mRNA1273 vs. BNT162b2: 1.22, 95% CI: 1.11–1.34; BNT162b2 vs. MVC-COV1901: 2.77, 95% CI: 2.27–3.39). The IR of different groups were calculated to support the decision making of the booster vaccine. Although AE were not uncommon for booster vaccines, almost all AE were not serious and predictable using estimated IR. This result can be used to optimize booster vaccine decision making.

show abstract

“…Fever, headache, fatigue, and pain at the injection site were the most known adverse reactions to COVID-19 vaccines, and overall, most adverse reactions were mild and short-lived [22, 23]. Although very rare, there have been reports of serious adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

“…Our results suggest that mRNA vaccines require booster vaccinations to induce adequate immunity, like inactivated vaccines such as the hepatitis B vaccine. Fever, headache, fatigue, and pain at the injection site were the most known adverse reactions to COVID-19 vaccines, and overall, most adverse reactions were mild and shortlived [22,23]. Although very rare, there have been reports of serious adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

Dynamics of anti-Spike IgG antibody titer after the third BNT162b2 COVID-19 vaccination in the Japanese health care workers

Ikezaki

Nomura

Shimono

2022

Preprint

View full text Add to dashboard Cite

Introduction: Many countries are administering a third dose of some coronavirus disease 2019 (COVID-19) vaccines, but the evaluation of vaccine-induced immunity is insufficient. This study aimed to evaluate anti-spike immunoglobulin G (IgG) titers in the health care workers after the third BNT162b2 vaccination. Methods: Dynamics of anti-spike IgG titers were assessed two months following the third BNT162b2 vaccination in 52 participants. All participants received the primary series of vaccination with BNT162b2 and received the third dose eight months after the second vaccination. Associations between anti-spike IgG titer, baseline characteristics, and adverse reactions were also evaluated. Results: The geometric mean titer of anti-spike IgG one month after the third vaccination was 17400 AU/ml, which increased to approximately 30 times immediately before the third vaccination and approximately twice that one month after the second vaccination. In addition, participants with anti-spike IgG titers less than 10000 AU/ml after the second vaccination tended to have higher increases in ant-spike IgG titers before and after the third vaccination. The decline rate of anti-spike IgG was significantly slower after the third vaccination as 35.7% than that after the second vaccination as 59.1%. The anti-spike IgG titer was significantly negatively associated with age (r = -0.31). Participants who had a headache at the vaccination showed significantly higher anti-spike IgG titer than those without a headache. Conclusions: The anti-spike IgG induced by primary immunization with BNT162b2 waned over time. The third dose of BNT162b2 substantially increased the anti-spike IgG with a slower decline rate.

show abstract

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Cited by 12 publications

References 8 publications

Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection

Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection

Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose

Dynamics of anti-Spike IgG antibody titer after the third BNT162b2 COVID-19 vaccination in the Japanese health care workers

Contact Info

Product

Resources

About